IDH1 and central nervous system cancer: A systematic review confirmed that adjuvant therapy with PCV was associated with improved OS and PFS versus TMZ in low-grade glioma but noted that the benefit was driven by patients with 1p/19q-codeleted tumors and IDH1 mutations (165).